RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions

Open access

RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions

A simple, sensitive and precise RP-HPLC-DAD method was developed and validated for the determination of olmesartan medoxomil (AT-II receptor blocker) in the presence of its degradation products. Olmesartan medoxomil and all the degradation products were resolved on a C18 column with the mobile phase composed of methanol, acetonitrile and water (60:15:25, V/V/V, pH 3.5 by orthophosphoric acid) at 260 nm using a photodiode array detector. The method was linear over the concentration range of 1-18 μg mL-1 and precise with RSD < 1 % in intra- and inter-day study. Excellent recoveries of 99.3 ± 0.9 to 100.8 ± 1.2% proved the accuracy of the method. Developed method was specific, as indicated by chromatographic resolution > 2.0 for each peak and sensitive with LOD 0.03 μg mL-1 and LOQ 0.1 μg mL-1. The method was used to study the drug degradation behavior under forced conditions. Four degradation products (DP-I, II, III, IV) were formed during the degradation study in 0.1 mol L-1 HCl whereas only DP-I, II and III were formed in water, 0.01 mol L-1 NaOH and 3% H2O2. No significant thermal or photolytic degradation was observed in solid drug. The method was applied successfully for the assay of olmesartan medoxomil in the tablet dosage form.

FDA, Draft Guidance for Industry: Stability Testing of Drug Substances and Drug Products, FDA, Rockville 1998.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A (R2), Step 5, ICH Geneva, Aug. 2003.

H.R. Brunner, The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview, J. Hum. Hypertens. 16 (2002) S13-S16; DOI: 10.1038/sj/jhh/1001391.

H. Koike, T. Konse, T. Sada, T. Ikeda, S. Hyogo, D. Hinman, H. Saito, and H. Yanagisawa, Olmesartan medoxomil, a novel potent angiotensin II blocker, Ann. Rep. Snakyo Res. Lab. 55 (2003) 1-91.

D.E. Mire, T.N. Silfani and M.K. Pugsley, A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker, J. Cardiovasc. Pharmacol. 46 (2005) 585-593; DOI: 10.1097/01.fjc.0000180902.78230.fd.

H. Koike, T. Sada and M. Mizuno, In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist, J. Hypertens. 19 (Suppl) (2001) S3-S14.

G.T. Warner and B. Jarvis, Olmesartan medoxomil, Drugs 62 (2002) 1345-1353.

O. Sagirli, A. Önal, S.E. Toker and D. Sensoy, Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies, Chromatographia 66 (2007) 213-218; DOI: 10.1365/s10337-007-0304-9.

K. Yoshihara, Y. Gao, H. Shiga, D.R. Wada and M. Hisaoka, Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients, Clin. Pharmacokin., 44 (2005) 1329-1342.

H. Nakamura, T. Inoue, N. Arakawa, Y. Shimizu, Y. Yoshigae, I. Fujimori, E.H. Nakamura, T. Inoue, N. Arakawa, Y. Shimizu, Y. Yoshigae, I. Fujimori, E. Shimakawa, T. Toyoshi and T. Yokoyama, Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models, Eur. J. Pharmacol. 512 (2005) 239-246; DOI: 10.1016/j.ejphar.2005.02.047.

V.V. Vaidya, S.M. Roy, S.M. Yetal, S.S. Joshi and S.A. Parekh, LC-MS-MS determination of olmesartan in human plasma, Chromatographia 67 (2008) 147-150; DOI: 10.1365/s10337-007-0453-x.

L. Dongyang, H. Pei, M. Nobuka, L. Xiaoming, L. Li and J. Ji, Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry, J. Chromatogr. B 856 (2007) 190-197; DOI: 10.1016/j.jchromb.2007.05.049.

N.J. Shah, B.N. Suhagia, R.R. Shah and N.M. Patel, Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form, Indian J. Pharm. Sci. 69 (2007) 834-836; DOI: 10.4103/0250-474X.39447.

C. Mustafa and A. Sacide, Development of a CZE method for the determination of olmesartan medoxomil in tablets, Chromatographia 66 (2007) 929-933; DOI: 10.1365/s10337-007-0424-2.

T. Murakami, H. Konno, N. Fukutsu, M. Onodera, T. Kawasaki and F. Kusu, Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques, J. Pharm. Biomed. Anal. 47 (2008) 553-559; DOI: 10.1016/j.jpba.2008.02.021.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guidelines, Validation of Analytical Procedure: Text and Methodology Q2 (R1), Current Step 4 version, ICH Geneva, Nov. 2005.

G.W. Ewing, Instrumental Methods of Chemical Analysis, 5th ed., Lippincott-Raven, Philadelphia 1995, pp. 484-486.

Z. Zhao, Q. Wang, E.W. Tsai, X.Z. Qin and D. Ip, Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS, J. Pharm. Biomed. Anal. 20 (1999) 129-36; DOI: 10.1016/S0731-7085(99)00004-7.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 250 250 15
PDF Downloads 93 93 6